Lincoln Pharmaceuticals Ltd issued a public notice on May 08, 2026, informing shareholders about the transfer of equity shares to the Investor Education and Protection Fund (IEPF) Authority. The notice was published in newspapers in compliance with Rule 6 of the IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, read with Section 124(6) of the Companies Act, 2013 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Basis for Share Transfer

Under the applicable provisions, companies are mandated to transfer equity shares to the IEPF Authority if dividends on those shares have remained unclaimed or unpaid for seven or more consecutive years. Lincoln Pharmaceuticals has accordingly initiated the process for shares on which dividends pertaining to the financial year 2018-2019 have not been claimed for seven or more consecutive years. Individual notices have been dispatched to concerned shareholders at their registered addresses as per the records of the company and its Registrar and Share Transfer Agent (RTA).

Key Details of the IEPF Transfer Process

The following table summarises the key parameters of the IEPF share transfer notice:

Process for Physical and Electronic Shareholders

The notice outlines distinct procedures for shareholders holding shares in physical and electronic form:

• Physical shareholders: The company will issue new share certificates against the original share certificates held by eligible shareholders. The new certificates will subsequently be converted into dematerialised form and transferred to the IEPF Authority's demat account. Original share certificates registered in the shareholder's name will stand automatically cancelled and will be treated as non-negotiable.
• Electronic shareholders: The company will instruct the depository to transfer the eligible shares directly to the IEPF Authority's demat account through the corporate action process.

Shareholder Action Required

Shareholders whose shares are liable to be transferred to the IEPF Authority are advised to lodge their claims for unclaimed or unpaid dividends with the company's RTA on or before 31st July, 2026. The company will transfer the shares to the IEPF Authority on the due date in accordance with the applicable rules. Once transferred, no claims in respect of such unpaid or unclaimed dividends and the underlying shares will be entertained by the company. Shareholders may thereafter file claims for such shares and any associated benefits, including dividends, directly with the IEPF Authority, details of which are available at www.iepf.gov.in . The list of shareholders whose shares are liable for transfer and related details are also available on the company's website at www.lincolnpharma.com .

The notice was signed by Trusha Shah, Company Secretary and Compliance Officer of Lincoln Pharmaceuticals Ltd, and was submitted to both the National Stock Exchange of India Limited and BSE Limited on May 08, 2026.

Lincoln Pharmaceuticals Limited has officially informed stock exchanges that it does not qualify as a Large Corporate under the SEBI regulatory framework for FY 2026-27. The Ahmedabad-based pharmaceutical company submitted its mandatory disclosure to both the National Stock Exchange of India Limited and BSE Limited on April 16, 2026.

Regulatory Compliance Disclosure

The company's disclosure references SEBI Circular No: SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, which establishes the framework for Large Corporate classification. Lincoln Pharmaceuticals confirmed that the specified criteria outlined in the circular are not applicable to the company as of March 31, 2026.

Official Documentation

The disclosure was formally signed by key company officials, demonstrating proper corporate governance compliance:

• Trusha Shah - Company Secretary & Compliance Officer
• Darshit Shah - Chief Financial Officer

Both officials digitally signed the documents on April 16, 2026, with timestamps showing the CFO's signature at 14:14:24 +05'30' and the Company Secretary's signature at 14:48:20 +05'30'.

Company Information

Lincoln Pharmaceuticals Limited operates from its registered office at "Lincoln House," Science City Road, Sola, Ahmedabad-380 060, Gujarat. The company maintains manufacturing facilities at Trimul Estate, Near Khatraj Chokadi, in Gandhinagar district. The pharmaceutical company holds WHO-GMP certification and maintains various quality management system certifications.

Regulatory Framework Context

The SEBI circular dated October 19, 2023, requires entities to make initial disclosures within 30 days from the beginning of the financial year if they qualify as Large Corporates. Lincoln Pharmaceuticals' proactive disclosure confirms its compliance with regulatory requirements while clarifying its non-applicability under the Large Corporate framework for FY 2026-27.